The stock of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has decreased by -3.52 when compared to last closing price of 9.38.Despite this, the company has seen a gain of 9.43% in its stock price over the last five trading days. globenewswire.com reported 2024-10-23 that Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
The 36-month beta value for DNA is at 1.12. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DNA is 35.44M, and currently, shorts hold a 23.10% of that float. The average trading volume for DNA on October 24, 2024 was 1.42M shares.
DNA’s Market Performance
The stock of Ginkgo Bioworks Holdings Inc (DNA) has seen a 9.43% increase in the past week, with a 12.14% rise in the past month, and a -32.78% fall in the past quarter. The volatility ratio for the week is 7.73%, and the volatility levels for the past 30 days are at 7.73% for DNA.. The simple moving average for the past 20 days is 11.20% for DNA’s stock, with a -67.11% simple moving average for the past 200 days.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at 17.46% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.97% of loss for the given period.
Volatility was left at 7.73%, however, over the last 30 days, the volatility rate increased by 7.73%, as shares surge +16.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.46% lower at present.
During the last 5 trading sessions, DNA rose by +9.43%, which changed the moving average for the period of 200-days by -85.50% in comparison to the 20-day moving average, which settled at $8.14. In addition, Ginkgo Bioworks Holdings Inc saw -86.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $9.27 back on Oct 23 ’24. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $918 using the latest closing price.
Che Austin, the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 99 shares at $8.85 during a trade that took place back on Oct 22 ’24, which means that Che Austin is holding shares at $876 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -4.07 for the present operating margin
- 0.59 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -4.87. The total capital return value is set at -0.51. Equity return is now at value -76.83, with -45.83 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at 0.54. The interest coverage ratio of the stock is -8065.74.
Currently, EBITDA for the company is -600.68 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 1.21. The receivables turnover for the company is 9.76for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.71.
Conclusion
In conclusion, Ginkgo Bioworks Holdings Inc (DNA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
